8 results about "Gene switch" patented technology

Disclosed are systems and methods for producing renewable alcohols by fermentative processes using selected promoters that differentially regulate the expression of genes encoding fermentation enzymes during the propagation and production phases of the fermentative processes. These systems and methods are able to increase production efficiency and yield in the conversion of sugars to renewable alcohols by fermentation in microbes. This is accomplished by the use of novel nucleic acid sequences that act as genetic switches to differentially control gene expression based on extra cellular stress; namely, stresses relating to fermentation processes. These sequences present a novel method for controlling endogenous gene expression without the need for the addition of heterlogous chemicals or signaling molecules.

The invention provides a method for high-throughput detection of gene switch ligand induced expression. Specifically, the invention provides a method for detecting gene switch ligand induced expression, a method for detecting target gene expression and application of the detection methods. The detection method provided by the invention has a small quantity demand on plasmids and viruses, and has the remarkable advantages of high distinction degree, low cost, rapidness, high-throughput test and the like, so that the expression of a target gene and the induced expression of a gene switch can be rapidly tested in a high-throughput manner.

Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.

The application provides a tumor cell dormancy and awakening marker tracing system (DormTracer), specifically, the system combines a gene switch and a site-specific recombination technology, expression of a reporter gene is driven by a recombination enzyme fused with a dormancy marker protein, the reporter gene is affected by a cell dormancy history, but does not affect the cycle of cell dormancy and proliferation, therefore, the tumor cell dormancy history can be traced, and the current instantaneous state of the cell is not limited to monitoring. The system can distinguish tumor cells in three states of proliferation, dormancy and dormancy awakening.

The risk with introducing manipulated T-cell is unforeseen adverse events. During the development of chimeric antigen receptor (CAR) T-cell therapies almost all clinical trial has shown some adverse events ranging from cytokine mediated toxicities to tissue damage and death. By the present invention, we aim to induce multiple layers of safety checkpoints. As a last resort we will be able to induce suicide in all cells which we have introduced to the body. Here we describe the scientific background to the parts of our suicide switch and the details regarding the proteins which are included. Safety switches are being tested on CAR-T cells, but they have a few drawbacks. Due to the limited space on the CAR vector, there is only room for one gene switch. Presently the results show they induce apoptosis in around 70-90% of cells, while the desired target is for all cells to be removed from the tissue. By utilising the space available on a synthetic chromosome, we can include multiple genes under Tet operons which allow us to turn multiple genes on / off. Life or death of a cell depends on the balance of the pro and anti-apoptotic proteins. The scale is always shifting a bit back and forth but only when tipped completely over the apoptotic cascade is initiated. By fine tuning the balance we aim to ensure that the hSync carrying cells have a survival advantage in the tumour in the absence of inducing agent. On the other hand, the moment that agent is administrated the cells will undergo apoptosis and express “find me” and “eat me” markers making sure they are removed without risk of tissue damage. The present invention encompasses compositions and methods for use in cellular gene therapeutics using a modular approach to genetically engineer cells to carry a synthetic chromosome having a regulatable system including one or more safety switches.

To provide a composition for ligand-inducible control of heterologous gene expression.SOLUTION: A composition comprises a polynucleotide encoding gene switch polypeptides for ligand-inducible control of heterologous gene expression, wherein the gene switch polypeptides comprise: a) a first gene switch polypeptide comprising a DNA binding domain fused to a first nuclear receptor ligand binding domain, and b) a second gene switch polypeptide comprising a transactivation domain fused to a second nuclear receptor ligand binding domain, wherein the first gene switch polypeptide and the second gene switch polypeptide are connected by a linker.SELECTED DRAWING: None

The invention discloses a vector for inducing and regulating expression of a target gene through a gene switch system and application of the vector. According to the gene switch system, the purpose of expressing the foreign protein on the adeno-associated virus vector with small foreign gene loading capacity can be achieved, some specific split structures have the unexpected advantage of extremely low leakage amount, and some specific split structures have the advantage of improving the expression quantity and the like.

The present invention provides a method for producing a multi-input / multi-output gene switch or transcription factor, and a multi-input / multi-output gene switch or transcription factor. [Solution] We have completed a method for producing a multi-input / multi-output gene switch or transcription factor, the essential steps of which are "fusing two or more transcription factor genes" and "introducing mutations into the fused transcription factor gene," and furthermore, we have been able to obtain a multi-input / multi-output gene switch or transcription factor using this method.